

Bamlanivimab and Etesevimab Authorized States, Territories, and U.S. Jurisdictions

Document Date: December 1, 2021

Bamlanivimab and etesevimab, administered together, are not authorized for use in states, territories, and U.S. jurisdictions in which the most recently published combined frequency of variants resistant to bamlanivimab and etesevimab exceeds 5%.

Since October 21, 2021, bamlanivimab and etesevimab are authorized for use in all U.S. states, territories, and jurisdictions as listed in Table 1.

FDA determines the list of authorized states, territories and U.S. jurisdictions considering [current variant frequency data](#), trends in variant frequency over time, the precision of the estimates and information regarding emerging variants of concern. FDA will update the list of states, territories, and U.S. jurisdictions in which bamlanivimab and etesevimab administered together are authorized as new data and information becomes available. Health care providers should refer to this webpage regularly for updates.

Health care providers should review a patient's travel and contact history within two weeks prior to infection. People who have traveled to, resided in, or had close contact with an infected individual from an area where the frequency of resistant variants to bamlanivimab and etesevimab exceeds 5% should not receive bamlanivimab and etesevimab.

Health care providers should also refer to Section 15 of the [Fact Sheet for Health Care Providers](#) for further details regarding specific variants and resistance.

Table 1: States, Territories, and U.S. Jurisdictions in which Bamlanivimab and Etesevimab Are Currently Authorized for Use

Alabama
Alaska
American Samoa
Arizona
Arkansas
California
Colorado
Commonwealth of the Northern Mariana Islands
Connecticut
Delaware
District of Columbia
Federated States of Micronesia
Florida
Georgia
Guam
Hawaii
Idaho
Illinois
Indiana

Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Republic of Palau
Republic of the Marshall Islands
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
U.S. Virgin Islands
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming